Cash/Burn From SEC Filing For Period:
Supernus is a specialty pharmaceuticals company focused on developing and commercializing products for the treatment of central nervous system, or CNS, diseases. The company's lead products, Oxtellar XR® and Trokendi XR®, are for the treatment of epilepsy. Supernus is also developing several product candidates to address large market opportunities in psychiatry, including SPN-810 for the treatment of Impulsive Aggression in patients with attention deficit hyperactivity disorder (ADHD) and SPN-812 for the treatment of ADHD.
Click drug data to see upcoming trial info and prior data
Drug | Disease
Stage | Exp Date
See What The Community Is Saying - Click To See Full Post